News
MIRM
24.42
+1.03%
0.25
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 17h ago
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Mirum Pharmaceuticals, Inc. Had a huge miss with a phase 2 study of its drug Limvarli for the treatment of biliary artesia in December 2023. Despite this, the biotech was still able to obtain FDA approval of the drug. The drug is being developed to treat liver disorders. Mirum will release results from two other ongoing phase 2b studies in mid-2024. These studies use another drug being developed in the pipeline, an iBAT inhibitor.
Seeking Alpha · 1d ago
Weekly Report: what happened at MIRM last week (0415-0419)?
Weekly Report · 1d ago
Some Bubbles Are Starting To Pop
The S&P 500 posted its worst weekly performance since March of 2023 this week. The yield on the 10-Year Treasury has risen to 4.62% from 3.9% in late February. Bubbles in the AI sector and high beta parts of the market are deflating. Rising interest rates are also impacting the commercial real estate sector.
Seeking Alpha · 2d ago
Stifel starts Mirum at buy, cites IBATi drug potential
Seeking Alpha · 5d ago
Analyst Ratings For Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for debilitating rare and orphan diseases. The company has an average price target of $52.0. 9 analysts have shared their insights on Mirum pharmaceuticals in the last three months. The 12-month price targets have decreased by 2.42%. The company is expected to reach $72.00 in the next year.
Benzinga · 6d ago
Mirum Pharmaceuticals Initiated at Buy by Stifel
Dow Jones · 6d ago
Mirum Pharmaceuticals Price Target Announced at $48.00/Share by Stifel
Dow Jones · 6d ago
Stifel Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $48
Benzinga · 6d ago
MIRUM PHARMACEUTICALS INC <MIRM.O>: STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $48
Reuters · 04/17 10:40
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughs
TipRanks · 04/16 20:35
Buy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial Outlook
TipRanks · 04/16 10:05
Weekly Report: what happened at MIRM last week (0408-0412)?
Weekly Report · 04/15 11:43
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. Granted inducement awards to nine new employees on April 10, 2024. Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. The stock options were granted to purchase 36,100 shares of common stock and 18,050 restricted stock units.
Barchart · 04/10 20:30
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Natera (NTRA) and Mirum Pharmaceuticals (MIRM)
TipRanks · 04/10 06:11
Weekly Report: what happened at MIRM last week (0401-0405)?
Weekly Report · 04/08 11:49
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)
TipRanks · 04/02 15:50
Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/02 15:48
Mirum Pharmaceuticals Price Target Maintained With a $58.00/Share by HC Wainwright & Co.
Dow Jones · 04/02 15:48
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Benzinga · 04/02 15:37
More
Webull provides a variety of real-time MIRM stock news. You can receive the latest news about Mirum Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.